Magazine Article | April 5, 2010

Monoclonal Antibodies: The Next Generation

Source: Life Science Leader

By Cliff Mintz Ph.D., Life Science Leader magazine.

The commercial success of therapeutic monoclonal antibodies (MAbs) to treat cancer, immune dysfunction, and infectious diseases has catapulted these once difficult-to-develop molecules to the forefront of modern molecular medicine. While MAbs are rapidly becoming commonplace in today’s therapeutic treatment armamentarium, it wasn’t until the mid to late 1990s that their full therapeutic and commercial potential were realized.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: